A prospective study of efficacy and safety of lenvatinib in patients with RAI-refractory differentiated thyroid cancer patients
Not Applicable
Recruiting
- Conditions
- thyroid cancer
- Registration Number
- JPRN-UMIN000021757
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 320
Inclusion Criteria
Not provided
Exclusion Criteria
a) undifferentiated and medullary carcinoma b) prior therapy with lenvatinib c) preteninuria d) with severe heart failure e) bleeding/atherothrombotic disorder, or use of anticoagulants f) with another active malignant tumors g) pregnant and/or lactating women h) judged to be unfit to this study by investigater
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression-free survival
- Secondary Outcome Measures
Name Time Method